TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Biogen stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $223.25 and its highest was $468.55 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $44.83B.
What is Biogen’s price target?
The average price target for Biogen is $426.28. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $647.00 ,the lowest forecast is $300.00. The average price target represents 41.72% Increase from the current price of $300.8.
What do analysts say about Biogen?
Biogen’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Oct 26, 2021 which is next month.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Jul 22, 2021. The company reported $2.988 earnings per share for the quarter, missing the consensus estimate of $4.549 by -$1.561.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of $22.23 which represents an annual dividend yield of N/A. Biogen’s last Notavailable dividend payment was on Feb 01, 2017. Biogen’s upcoming ex-dividend date is Feb 02, 2017
What is Biogen’s EPS estimate?
Biogen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biogen have?
Biogen has 149,030,000 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $2.988 in its last earnings report, missing expectations of $4.549. Following the earnings report the stock price went up 0.756%.
Which hedge fund is a major shareholder of Biogen?
Among the largest hedge funds holding Biogen’s share is PRIMECAP Management Co. It holds Biogen’s shares valued at 6B.